An innovation to mimic patient’s cancer relapsing conditions.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
STC allogeneic vaccine
Mimicking patient’s mechanism of relapse to increase panel of targets. Validation based on proteome. (LC/MS)
Invasive: tumor biopsy needed, HLA restriction.
Limited / Validation based on gene
extrapolation. (NGC platform)
Non immunogenic targets, Potential
safety issues with viral vectors.
“Patient / Patient”
Complex, long and costly.
Brenus’ manufacturing process overpasses the lack of immunogenicity & educates the immune system with visible and multi-specific targets
Selection criteria of starting material (Allogeneic tumor cell lines)
Brenus’ manufacturing process overpasses the lack of antigenicity & educates the immune system with a broad & higher quality range of tumor antigens